RE:RE:The big one..."e.g. co. should have highlighted one-time expenses that will not recur like $921,000 in legal fees." News release:
- "Continued to assess possible corporate strategies to support the accelerated growth of the Company along with stated objective of uplisting to Nasdaq."
- "...over the past quarter we remained very active with strategic corporate initiatives aimed towards achieving a stated objective related to uplisting Ceapro to an international stock exchange."
CZO has talked about a potential reverse-merger to list on NASDAQ as one path. Having lawyers go over, in great detail, the corporate history and documents of a number of different companies to make sure there are no legal skeletons in the closet, and potential patent lawyers go over patents could be alot of work. CZO wouldn't want to marry a company with legal skeletons in the closet that wasn't what it claimed. A reverse-merger would be a huge strategic move with zero tolerance for errors and CZO is also talking about "accelerating growth". What assets and IP might be being looked at? CZO says it is "very active" with "corporate initiatives". How many paths are being investigated to find the best one? One of these days, potentially soon, the morons on this message board focuses on the base business could wake up and find a price placed on CZO's pipeline that is now before key catalysts. CZO has talked about a potential simultaneous PGX licensing deal to support a NASDAQ listing in the past. Gilles said it is in discussions with serious companies concerning the $4 billion CoQ10 market aand that could require legal fees too. The avenanthramide trial will start producing results in humans next week too and the fibrosis drug is near a full clinical trial decision. Avalyn raised $C80 million cash going into its Phase I clinical trial. CZO put the section on its fibrosis drug in bold lettering as if to draw attention to it and notes an "important finding":
Yeast Beta Glucan (YBG) - Potential Inhalo-Therapeutic
- "Following the announcement of encouraging results made at two major international conferences earlier this year demonstrating that PGX-YBG is respirable and able to safely and reliably reprogram macrophages in the lungs in pre-clinical mouse models, additional research at McMaster University clearly showed that PGX-YBG gets into the macrophage cell. This important finding further supports the potential of YBG to act as a stand-alone and/or a carrier for other bioactives when transported by macrophages cells."
By making an "important finding" that PGX-YBG can clearly get into macrophages has Gilles made another important breakthrough? Has Gilles discovered a way to hijack macrophages and deliver bioactive throughout the body to remote sites as a booster rocket to PGX carrier delivery? Is that what explains the blowout CoQ10 bioavailability results vs. the industry gold standard CZO has produced? What other companies can acheive this with their CoQ10 carriers in what Gilles said was a $4 billion market? At the AGM Gilles said it was in talks with serious companies that understand bioavailability as a unique selling point.
Trojan Horse:
- "Of interest, the size of PGX processed YBG particles (around 5 microns) would allow them to be “swallowable” by macrophages that would carry them to remote sites in the body. Thus, the loading of drugs onto PGX YBG is currently under further investigation, since numerous research studies suggest that YBG cells being swallowed by macrophages could be utilized as “Trojan Horses” to carry bioactives (potentially CoQ10, antioxidants, pain killers or potent pharmaceutical drugs) into the body to the target tissue." Aug. 24, 2022 CZO news release